Biohacking for cures: what you need to know.
Academic rigor, journalistic flair
Articles on Big Pharma
Displaying 1 - 20 of 60 articles
Big Pharma in Canada is far behind the curve when it comes to disclosing what payments to health-care professionals are for.
Noted physician and author Atul Gawande was named CEO of a new health care venture aimed at cutting costs and improving care. But the most important man to keep an eye on in this effort isn't Gawande. It's the middleman.
The US is currently short on 182 drugs and medical supplies. The problem isn't new, but it's frustrating health care workers.
The logic behind U.S. president Donald Trump's proposal that Canada and other countries have been “free-riding” off high prices in the United States is bizarre at best.
How a technology born from finance – the blockchain – can help the pharmaceutical industry to carry out clinical trials that protect patients.
The Saint Regis Mohawk tribe has struck a multimillion-dollar deal with Allergan. But the deal may do more harm than good.
Your guide to a public health crisis that's likely to get worse.
How can we fight the opioid epidemic? Redesign the drugs, rethink how we assess patients and mandate prescription monitoring.
Drug prices in Australia are three times higher than in New Zealand. A key reason is the lack of transparency about taxpayer subsidies for Big Pharma and the companies' own finances.
In an era when opinion often trumps evidence in public health issues, it's time to support and invest in evidence-based medicine to protect the public from dangerous, poorly informed beliefs.
The state of Ohio filed a lawsuit against opioid manufacturers. Will their legal arguments hold up in court – and what will it mean for other cities and states going after big pharma?
Drug companies funded more than 116,000 educational events for doctors over four years. Now you can find out exactly which companies footed the bills and how much they paid.
More of us are labelled as sick with the constantly changing diagnostic cut-offs for diseases. Now an international expert panel has drafted a list of things to consider before setting new thresholds.
Intuitively, it might seem desirable to speed up access to medicines. But this means more drugs will be approved that may subsequently prove unsafe or ineffective.
We have barely begun to tap into the pharmaceutical potential of the most diverse animals of all.
Children's cancer is a rare disease, which means the market is small and pharmaceutical companies have few incentives to develop drugs for these cancers.
The maker of the EpiPen has raised the price of two injectable treatments to about US$600, six times the price nine years ago. Why do drug companies do this? Because they can. The FDA ends up helping.
Feel-good fudges designed to boost staff morale are giving way to tangible projects which can be reported to shareholders.
An important new study in the United States has found doctors who receive just one cheap meal from a drug company tend to prescribe a lot more of that company's products.
Top contributors
-
Senior Research Fellow, Bioethics, University of Sydney
-
Senior Research Fellow, Bond University
-
Assistant Professor, School of Law, University of Canberra
-
Professor of Bioethics & Medicine, Sydney Health Ethics, University of Sydney
-
Ken Harvey is a Friend of The Conversation.
Associate Professor, School of Public Health and Preventive Medicine, Monash University
-
Associate Professor Politics and Policy Studies, Deakin University
-
Postdoctoral Researcher, Sydney Health Ethics, University of Sydney
-
Lecturer in Accounting & Management, Lancaster University
-
Professor Emeritus of Health Policy and Management, York University, Emergency Physician at University Health Network, Associate Professor of Family and Community Medicine, University of Toronto
-
Brett Montgomery is a Friend of The Conversation.
Senior Lecturer in General Practice, University of Western Australia
-
Adjunct Professor, Murdoch University
-
Dean, University of Wollongong
-
Professor; Head, School of Clinical Sciences, Queensland University of Technology
-
Research Leader, Critical and Ethical Mental Health research group, Robinson Research Institute, University of Adelaide
-
Professor of Accounting, Durham University
